All In Biotech

Drug Trial Radar · NCT01568073

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study

Last checked: Nov 19, 2026Latest source record: Sep 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Mar 2011

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Bial - Portela C S.A.Industry
Sponsor type
Industry
First posted
Apr 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 83 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to demonstrate the efficacy and safety of BIA 9-1067, compared with entacapone or placebo, when administered with the existing treatment of L-DOPA plus a Dopa Decarboxylase Inhibitor (DDCI), in patients with Parkinson's Disease (PD) and end-of-dose motor fluctuations.

Conditions

  • Parkinson's Disease

Interventions

  • BIA 9-1067Drug

    5, 25 and 50 mg of BIA 9-1067 (once-daily)

  • EntacaponeDrug

    200 mg entacapone (concomitantly with each L-dopa/DDCI dose)

  • PlaceboDrug

    200 mg

  • LevodopaDrug

  • CarbidopaDrug

    DOPA decarboxylase inhibitor

  • BenserazideDrug

    DOPA decarboxylase inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,Time frame: 14 to 15 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bial - Portela & Cª, S.A.

    S. Mamede Do Coronado, Portugal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.